Cannabis Science CEO, Dr. Robert Melamede PhD, to Speak at "First-Ever Live and On Demand Continuing Education in Medical Marijuana Science, Law and Horticulture" With 420 University
COLORADO SPRINGS, Colo. - Cannabis Science, Inc. (OTCBB:CBIS - News) a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to report that its CEO Dr. Robert Melamede PhD will be speaking at "The Science and Compassionate Care Seminar" to be held in Kalamazoo, Mich., on July 10 -- 11.
Dr. Melamede, retired Chairman of the Biology Department at the University of Colorado at Colorado Springs, is a pioneer in endocannibinoid research. He has joined the 420 University Advisory Board as part of Cannabis Science's commitment to educating the public about the importance of cannabis in maintaining good health, not just in treating disease.
Participants can attend the live two-day, onsite seminar for $295, but the seminar will also be streamed live on the Internet as the result of an agreement between 420 University and uVuMobile, which will deliver an industry first, utilizing uVuMobile's proprietary VXStream platform to deliver it to viewers on a pay-per-view basis utilizing uVuMobile's VXStream platform for only $99. Following the two-day event, an encore-archived presentation of the complete seminar will be available through video on-demand for $99. 420 University is a wholly owned subsidiary of 420 Ventures, LLC. Information about the event is available online at www.420seminars.com.
Richard Cowan, Cannabis Science CFO, noted, "These seminars help educate the public as well as people who want to become involved in some part of the cannabis industries, but invariably they also create new opportunities for Cannabis Science resulting from people meeting Dr. Melamede."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.